Biomarker: GHSR

Biomarker subtype: DNA

Clinical application: diagnosis(non-invasive detection)

Histology type: endometrioid endometrial carcinoma

Country: The Netherlands

Region: Amsterdam

Cohort age: 40-86

Sample type : urine

Clinical method: quantitative methylation specifc PCR (qMSP)

Expression pattern : increased methylation levels

Expression elevation: The correlation between Cq ratios of each DNA methylation marker between paired urine fractions of both patients and controls was assessed using Spearman’s rank correlation. Correlation coefficient r was defined as moderate (r?=?0.40–0.59), strong (r?=?0.60–0.79), or very strong (r?=?0.80–1.00).

Statictics: Range

Cohort age: 40-86

Description: All DNA methylation markers showed increased methylation levels in patients as compared to controls, in all urine fractions. The highest diagnostic potential for endometrial cancer detection in urine was found in full void urine, with area under the receiver operating characteristic curve values ranging from 0.86 to 0.95

Expression figure legend: DNA methylation levels of GHSR, SST, and ZIC1 in full void urine, urine sediment and urine supernatant from healthy female controls and women with endometrial cancer (EC)

Expression figure link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640380/figure/Fig1/

Approved symbol: GHSR

Approved name: growth hormone secretagogue receptor

Locus type: gene with protein product

HGNC ID: HGNC:4267

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4267

Symbol status: Approved

Subgroup: G protein-coupled receptors, Class A rhodopsin-like

OMIM: 601898

Omim link: https://www.omim.org/entry/601898